Mawdsleys is delighted to now be partnering with Morningside Pharmaceuticals as an additional distributor to supply their contract and non-contract products to hospitals.   Morningside has a portfolio of 242 generic and branded licensed medicines in the UK and EU and is a proud manufacturer and supplier to NHS Trusts,…

As the end of the Transition Period on 31st December 2020 draws ever closer, pharmaceutical companies are preparing for life outside the EU Single Market and Customs Union. Holding additional stock could provide a buffer against any potential border disruption that could occur during the transition to the controls that…

Mawdsleys adopts solar technology across our fleet   Aware of our impact on the environment as a rapidly growing business, Mawdsleys are working with solar transport solutions company, TRAILAR, to make their solar technology standard across our fleet.     Steve Charlesworth, Logistics Director at Mawdsleys says “We identified TRAILAR’s technology as a green option…

Mawdsleys is delighted to be partnering with Manx Healthcare to distribute their contract products to hospitals in England.   Hospitals can view and check live stock levels and contract prices on Mawdsleys Online, and order in their normal way. For any queries hospitals can contact their Regional Hospital Account Manager or…

Mawdsleys is delighted to be partnering with Cipla to distribute their contract and non contract products to hospitals from 1st June 2020.   Cameron McMaster, Associate Director UK Sales at Cipla says “We have chosen Mawdsleys to take full charge of our Hospital distribution due to their experience and reputation…

Mawdsleys and Meabco A/S have launched a Named Patient Supply program to allow Oncologists within the European Union (EU) to obtain access to BP-C1 on an unlicensed basis for the treatment of metastatic breast cancer and incurable pancreatic cancer.   BP-C1 is a new benzene-poly-carboxylic acids complex with cis-diammineplatinum (II)…